Brokerages expect Fibrocell Science Inc (NASDAQ:FCSC) to report earnings of ($0.23) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Fibrocell Science’s earnings. The lowest EPS estimate is ($0.23) and the highest is ($0.22). Fibrocell Science posted earnings of ($0.33) per share in the same quarter last year, which would indicate a positive year over year growth rate of 30.3%. The firm is expected to issue its next quarterly earnings results on Thursday, March 8th.
On average, analysts expect that Fibrocell Science will report full year earnings of ($1.63) per share for the current fiscal year. For the next year, analysts expect that the company will report earnings of ($0.87) per share, with EPS estimates ranging from ($1.02) to ($0.71). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side analysts that cover Fibrocell Science.
Fibrocell Science (NASDAQ:FCSC) last issued its quarterly earnings results on Monday, November 13th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.07.
Shares of Fibrocell Science (FCSC) traded down $0.02 during midday trading on Friday, reaching $0.72. 385,108 shares of the company were exchanged, compared to its average volume of 976,152. Fibrocell Science has a one year low of $0.61 and a one year high of $4.64. The stock has a market cap of $18.65, a PE ratio of -0.39 and a beta of 0.35.
In other Fibrocell Science news, major shareholder Randal J. Kirk purchased 2,727,273 shares of the stock in a transaction that occurred on Monday, December 11th. The stock was bought at an average cost of $0.77 per share, with a total value of $2,100,000.21. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 2.10% of the company’s stock.
An institutional investor recently bought a new position in Fibrocell Science stock. Pura Vida Investments LLC acquired a new stake in shares of Fibrocell Science Inc (NASDAQ:FCSC) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 297,000 shares of the company’s stock, valued at approximately $909,000. Pura Vida Investments LLC owned approximately 2.02% of Fibrocell Science as of its most recent filing with the Securities and Exchange Commission. 31.64% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: This news story was posted by American Banking News and is owned by of American Banking News. If you are reading this news story on another domain, it was illegally copied and reposted in violation of US & international trademark and copyright law. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2018/01/21/fibrocell-science-inc-fcsc-expected-to-post-earnings-of-0-23-per-share.html.
Fibrocell Science Company Profile
Fibrocell Science, Inc is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Fibrocell Science Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fibrocell Science and related companies with MarketBeat.com's FREE daily email newsletter.